Danhong Injection targets CaMKII through Dihydrotanshinone I to alleviate cardiomyocyte death and inflammation in viral myocarditis
Junxia Zhang(Jiangsu Cancer Hospital), Yan Zhang(China West Normal University), Dao Wen Wang(Tongji Hospital), Chengcheng Zhao(Tongji Hospital), Quan Li(Shanghai Jiao Tong University), Yiwu Zhou(Sichuan University), Haibao Shang(Peking University), Erdan Dong(Qingdao University), Wen Zheng(Peking University), Huihui Li(Xiangya Hospital Central South University), Ye Li(Hohai University), Chen Chen(Tongji Hospital), Mao Zhang(Dalian Medical University), Wenjia Zhang(Tongji University), Luyun Wang(Tongji Hospital), Xiaochuan Li(Peking University), Li Fan(Fudan University)
Cited by 2
Related Papers
CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress–induced myocardial necroptosis
|Nature Medicine|2016|791
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
|Annals of Oncology|2019|475
Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles
|Biomaterials|2012|278
An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques
|Nature Communications|2020|247